Dalutrafusp alfa is under clinical development by Agenus and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dalutrafusp alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dalutrafusp alfa overview

Dalutrafusp alfa (AGEN-1423) is under development for the treatment of solid tumor and metastatic pancreatic ductal adenocarcinoma, metastatic colorectal adenocarcinoma with liver metastases. It is based on retrocyte display technology and secant yeast display technology. It is administered through intravenous route. The therapeutic candidate is a bi-specific monoclonal antibody act by targeting immune checkpoint like CD73 and TGF-B.

It was under development for the treatment of advanced solid tumors including gastric or gastroesophageal junction adenocarcinoma and pancreatic cancer.

Agenus overview

Agenus, formerly, Antigenics, is a clinical-stage immuno-oncology company that discovers, develops and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

For a complete picture of Dalutrafusp alfa’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.